Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Initial high-efficacy disease-modifying therapy in multiple sclerosis: A nationwide cohort study

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Efficacy and Safety of Rozanolixizumab in Moderate to Severe Generalized Myasthenia Gravis: A Phase 2 Randomized Control Trial

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Time trends in incidence, comorbidity, and mortality of ischemic stroke in Denmark, 1996-2016

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Clinical characterization of delayed alcohol-induced headache: A study of 1,108 participants

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Serum neurofilament light as a biomarker in progressive multiple sclerosis

    Publikation: Bidrag til tidsskriftReviewpeer review

  5. Evaluation of inflammatory lesions over 2 years in facioscapulohumeral muscular dystrophy

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Exposure to passive smoking during adolescence is associated with an increased risk of developing multiple sclerosis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Treatment- and population-specific genetic risk factors for anti-drug antibodies against interferon-beta: a GWAS

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Biomarkers of inflammation and epithelial barrier function in multiple sclerosis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

OBJECTIVE: To determine the effectiveness of high-efficacy disease-modifying therapies (heDMTs) vs medium-efficacy disease-modifying therapies (meDMT) as the first treatment choice in treatment-naive patients with multiple sclerosis (MS) on disability worsening and relapses. We assessed this using a nationwide population-based MS registry.

METHODS: We identified all patients starting a heDMT as first-time treatment from the Danish Multiple Sclerosis Registry and compared treatment outcomes with a propensity score matched sample of patients starting meDMT.

RESULTS: We included 388 patients in the study: 194 starting initial therapy with heDMT matched to 194 patients starting meDMT. At 4 years of follow-up, the probabilities of a 6-month confirmed Expanded Disability Status Scale (EDSS) score worsening were 16.7% (95% confidence interval [CI] 10.4%-23.0%) and 30.1% (95% CI 23.1%-37.1%) for heDMT and meDMT initiators, respectively (hazard ratio [HR] 0.53, 95% CI 0.33-0.83, p = 0.006). Patients initiating heDMT also had a lower probability of a first relapse (HR 0.50, 95% CI 0.37-0.67). Results were similar after pairwise censoring and in subgroups with high baseline activity, diagnosis after 2006, or information on baseline T2 lesion load.

CONCLUSION: We found a lower probability of 6-month confirmed EDSS score worsening and lower probability of a first relapse in patients starting a heDMT as first therapy, compared to a matched sample starting meDMT.

CLASSIFICATION OF EVIDENCE: This study provides Class III evidence that for patients with MS, starting heDMT lowers the risk of EDSS worsening and relapses compared to starting meDMT.

OriginalsprogEngelsk
Artikelnummer32636328
TidsskriftNeurology
Vol/bind95
Udgave nummer8
Sider (fra-til)e1041-e1051
Antal sider11
ISSN0028-3878
DOI
StatusUdgivet - 25 aug. 2020

Bibliografisk note

© 2020 American Academy of Neurology.

ID: 61323617